Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659900 | 0.86 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL28300994 | 0.84 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL2356393 | 0.82 | NPC1 (0.68) | CYP11B1CYP11B2CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL7582709 | 0.82 | CYP2A6 (0.53) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL8360922 | 0.79 | CYP2A6 (0.51) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL6222583 | 0.79 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL21588612 | 0.79 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL2652567 | 0.79 | AXL (0.56) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL19257504 | 0.79 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 | |
| SCHEMBL2649040 | 0.79 | CYP11B2 (0.54) | CYP11B1CYP11B2CYP2A6CYP3A4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| EP-1381606-B1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6900215-B2 | For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders | MERCK SHARP & DOHME LTD. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2002-12-19 | — | — | US | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193385-A1 | Imidazo-pyrimidine derivatives as ligands for gaba receptors | GABRA3, GABRA1, GABRA2 | CYP11B1 1108/4885CYP11B2 952/4885CYP2A6 552/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | CYP11B1 424/4885CYP11B2 374/4885CYP2A6 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.